Login to Your Account



Oh Canada, Where's the Capital?

Stem Cell Therapy Moves to Reinvent Itself, Raise Value

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, February 25, 2013

After seeing its clinical program stall following the failure of a Phase IIb trial testing NTx-265 in acute stroke, Stem Cell Therapeutics Corp. is reinventing itself. (See BioWorld Today, May 26, 2010.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription